Risikoen var øget i de tilfælde, hvor rosiglitazon blev lagt oven i insulinbehandling, og hos patienter i nitratbehandling for iskæmisk hjertesygdom.
This risk was increased when rosiglitazone was added to established insulin and in patients receiving nitrates for known ischaemic heart disease.